Combigan
Migraine, Open-angle glaucoma, Migraine Disorders + 6 more
Treatment
20 Active Studies for Combigan
Treatment for
Migraine
What is Combigan
Timolol
The Generic name of this drug
Treatment Summary
Brimonidine is a drug used to treat glaucoma and can be used to reduce facial redness associated with rosacea. It is a type of alpha-adrenergic agonist, which works by reducing the amount of fluid in the eye and increasing the drainage of fluid. Brimonidine is considered to be a safer alternative to beta-blockers, as it does not have significant cardiovascular side effects. It was approved by the FDA in 1996 and was later approved as Mirvaso in 2013 for rosacea treatment.
Timoptic
is the brand name
Combigan Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Timoptic
Timolol
1978
167
Effectiveness
How Combigan Affects Patients
Brimonidine is an alpha-2 adrenergic receptor agonist, which means it is designed to target and activate the alpha-2 adrenergic receptor. This helps reduce the risk of side effects such as low blood pressure, slow heart rate, and drowsiness. Brimonidine also reduces the chances of unwanted eye effects caused by alpha-1 receptors, like blanching, pupil dilation, and eyelid retraction. After two hours, brimonidine helps reduce eye pressure, and can maintain this effect for up to a year. Additionally, it can reduce inflammation and redness in the skin, and may even have neuro
How Combigan works in the body
Brimonidine is commonly used to treat glaucoma and facial redness. In the eye, it works by activating alpha-2 adrenoceptors, which reduces norpinephrine activity, decreases aqueous humor production, and increases uveoscleral outflow. This helps to lower intraocular pressure which reduces the risk of vision loss. When applied topically to the skin, brimonidine constricts blood vessels, reducing redness and inflammation. This makes it effective for treating facial redness caused by rosacea.
When to interrupt dosage
The recommended dose of Combigan is contingent upon the identified condition, including Open Angle Glaucoma, facial erythema and Ocular Hypertension. The extent of dosage changes as per the technique of delivery featured in the table below.
Condition
Dosage
Administration
Migraine Disorders
5.0 mg/mL, , 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg/mL, 6.8 mg/mL, 6.83 mg/mL, 2.56 mg/mL, 5.12 mg/mL, 0.5 %, 0.25 %, 3.4 mg/mL, 0.1 mg/mL
Ophthalmic, Solution - Ophthalmic, Solution, , Oral, Tablet, Tablet - Oral, Solution / drops - Ophthalmic, Solution / drops, Solution, gel forming, extended release, Solution, gel forming, extended release - Ophthalmic, Liquid - Ophthalmic, Suspension / drops, Suspension - Ophthalmic, Suspension, Suspension / drops - Ophthalmic, Liquid, Solution, gel forming / drops, Solution, gel forming / drops - Ophthalmic
Open-angle glaucoma
5.0 mg/mL, , 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg/mL, 6.8 mg/mL, 6.83 mg/mL, 2.56 mg/mL, 5.12 mg/mL, 0.5 %, 0.25 %, 3.4 mg/mL, 0.1 mg/mL
Ophthalmic, Solution - Ophthalmic, Solution, , Oral, Tablet, Tablet - Oral, Solution / drops - Ophthalmic, Solution / drops, Solution, gel forming, extended release, Solution, gel forming, extended release - Ophthalmic, Liquid - Ophthalmic, Suspension / drops, Suspension - Ophthalmic, Suspension, Suspension / drops - Ophthalmic, Liquid, Solution, gel forming / drops, Solution, gel forming / drops - Ophthalmic
Migraine
5.0 mg/mL, , 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg/mL, 6.8 mg/mL, 6.83 mg/mL, 2.56 mg/mL, 5.12 mg/mL, 0.5 %, 0.25 %, 3.4 mg/mL, 0.1 mg/mL
Ophthalmic, Solution - Ophthalmic, Solution, , Oral, Tablet, Tablet - Oral, Solution / drops - Ophthalmic, Solution / drops, Solution, gel forming, extended release, Solution, gel forming, extended release - Ophthalmic, Liquid - Ophthalmic, Suspension / drops, Suspension - Ophthalmic, Suspension, Suspension / drops - Ophthalmic, Liquid, Solution, gel forming / drops, Solution, gel forming / drops - Ophthalmic
inadequate response to other therapeutic measures
5.0 mg/mL, , 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg/mL, 6.8 mg/mL, 6.83 mg/mL, 2.56 mg/mL, 5.12 mg/mL, 0.5 %, 0.25 %, 3.4 mg/mL, 0.1 mg/mL
Ophthalmic, Solution - Ophthalmic, Solution, , Oral, Tablet, Tablet - Oral, Solution / drops - Ophthalmic, Solution / drops, Solution, gel forming, extended release, Solution, gel forming, extended release - Ophthalmic, Liquid - Ophthalmic, Suspension / drops, Suspension - Ophthalmic, Suspension, Suspension / drops - Ophthalmic, Liquid, Solution, gel forming / drops, Solution, gel forming / drops - Ophthalmic
insufficient response to beta-blockers
5.0 mg/mL, , 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg/mL, 6.8 mg/mL, 6.83 mg/mL, 2.56 mg/mL, 5.12 mg/mL, 0.5 %, 0.25 %, 3.4 mg/mL, 0.1 mg/mL
Ophthalmic, Solution - Ophthalmic, Solution, , Oral, Tablet, Tablet - Oral, Solution / drops - Ophthalmic, Solution / drops, Solution, gel forming, extended release, Solution, gel forming, extended release - Ophthalmic, Liquid - Ophthalmic, Suspension / drops, Suspension - Ophthalmic, Suspension, Suspension / drops - Ophthalmic, Liquid, Solution, gel forming / drops, Solution, gel forming / drops - Ophthalmic
requiring adjunctive or replacement therapy
5.0 mg/mL, , 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg/mL, 6.8 mg/mL, 6.83 mg/mL, 2.56 mg/mL, 5.12 mg/mL, 0.5 %, 0.25 %, 3.4 mg/mL, 0.1 mg/mL
Ophthalmic, Solution - Ophthalmic, Solution, , Oral, Tablet, Tablet - Oral, Solution / drops - Ophthalmic, Solution / drops, Solution, gel forming, extended release, Solution, gel forming, extended release - Ophthalmic, Liquid - Ophthalmic, Suspension / drops, Suspension - Ophthalmic, Suspension, Suspension / drops - Ophthalmic, Liquid, Solution, gel forming / drops, Solution, gel forming / drops - Ophthalmic
Glaucoma
5.0 mg/mL, , 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg/mL, 6.8 mg/mL, 6.83 mg/mL, 2.56 mg/mL, 5.12 mg/mL, 0.5 %, 0.25 %, 3.4 mg/mL, 0.1 mg/mL
Ophthalmic, Solution - Ophthalmic, Solution, , Oral, Tablet, Tablet - Oral, Solution / drops - Ophthalmic, Solution / drops, Solution, gel forming, extended release, Solution, gel forming, extended release - Ophthalmic, Liquid - Ophthalmic, Suspension / drops, Suspension - Ophthalmic, Suspension, Suspension / drops - Ophthalmic, Liquid, Solution, gel forming / drops, Solution, gel forming / drops - Ophthalmic
Open Angle Glaucoma
5.0 mg/mL, , 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg/mL, 6.8 mg/mL, 6.83 mg/mL, 2.56 mg/mL, 5.12 mg/mL, 0.5 %, 0.25 %, 3.4 mg/mL, 0.1 mg/mL
Ophthalmic, Solution - Ophthalmic, Solution, , Oral, Tablet, Tablet - Oral, Solution / drops - Ophthalmic, Solution / drops, Solution, gel forming, extended release, Solution, gel forming, extended release - Ophthalmic, Liquid - Ophthalmic, Suspension / drops, Suspension - Ophthalmic, Suspension, Suspension / drops - Ophthalmic, Liquid, Solution, gel forming / drops, Solution, gel forming / drops - Ophthalmic
Ocular Hypertension
5.0 mg/mL, , 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg/mL, 6.8 mg/mL, 6.83 mg/mL, 2.56 mg/mL, 5.12 mg/mL, 0.5 %, 0.25 %, 3.4 mg/mL, 0.1 mg/mL
Ophthalmic, Solution - Ophthalmic, Solution, , Oral, Tablet, Tablet - Oral, Solution / drops - Ophthalmic, Solution / drops, Solution, gel forming, extended release, Solution, gel forming, extended release - Ophthalmic, Liquid - Ophthalmic, Suspension / drops, Suspension - Ophthalmic, Suspension, Suspension / drops - Ophthalmic, Liquid, Solution, gel forming / drops, Solution, gel forming / drops - Ophthalmic
Warnings
Combigan Contraindications
Condition
Risk Level
Notes
Lung Diseases, Obstructive
Do Not Combine
Sinus Bradycardia
Do Not Combine
Shock, Cardiogenic
Do Not Combine
Atrioventricular Block
Do Not Combine
Asthma
Do Not Combine
Heart Failure
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Timolol may interact with Pulse Frequency
There are 20 known major drug interactions with Combigan.
Common Combigan Drug Interactions
Drug Name
Risk Level
Description
4-Bromo-2,5-dimethoxyphenethylamine
Major
The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Timolol.
4-Methoxyamphetamine
Major
The therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Timolol.
Abediterol
Major
Timolol may decrease the bronchodilatory activities of Abediterol.
Adrafinil
Major
The therapeutic efficacy of Adrafinil can be decreased when used in combination with Timolol.
Agrostis gigantea pollen
Major
The risk of a hypersensitivity reaction to Agrostis gigantea pollen is increased when it is combined with Timolol.
Combigan Toxicity & Overdose Risk
The toxic dose of brimonidine in mice is 50 mg/kg, and in rats it is 100 mg/kg. Overdosing on brimonidine can cause low blood pressure, weakness, vomiting, drowsiness, slow heart rate, abnormal heart rhythms, narrowed pupils, difficulty breathing, low body temperature, and seizures. Treatment for a brimonidine overdose includes supportive care. Based on animal studies, brimonidine was not found to cause birth defects or fertility problems. It is not recommended to use brimonidine in pregnant or breastfeeding women, infants under the age of 2, or pediatric patients under the age of 18.
Combigan Novel Uses: Which Conditions Have a Clinical Trial Featuring Combigan?
114 active trials are underway to assess the potential of Combigan in providing relief from Open Angle Glaucoma, inadequately controlled intraocular pressure and Open Angle Glaucoma.
Condition
Clinical Trials
Trial Phases
Open-angle glaucoma
45 Actively Recruiting
Phase 2, Not Applicable, Phase 3, Phase 4, Early Phase 1, Phase 1
Open Angle Glaucoma
10 Actively Recruiting
Phase 3, Not Applicable, Phase 4
Ocular Hypertension
10 Actively Recruiting
Phase 3, Phase 1, Phase 2, Not Applicable, Phase 4
requiring adjunctive or replacement therapy
0 Actively Recruiting
inadequate response to other therapeutic measures
0 Actively Recruiting
Migraine Disorders
1 Actively Recruiting
Phase 3
Migraine
50 Actively Recruiting
Phase 4, Not Applicable, Phase 1, Phase 3, Phase 2, Early Phase 1
Glaucoma
0 Actively Recruiting
insufficient response to beta-blockers
0 Actively Recruiting
Combigan Reviews: What are patients saying about Combigan?
5
Patient Review
7/8/2015
Combigan for Wide-Angle Glaucoma
5
Patient Review
7/1/2020
Combigan for Increased Pressure in the Eye
5
Patient Review
6/29/2018
Combigan for Increased Pressure in the Eye
4
Patient Review
8/4/2016
Combigan for Increased Pressure in the Eye
4
Patient Review
10/12/2014
Combigan for Increased Pressure in the Eye
4
Patient Review
2/23/2018
Combigan for Increased Pressure in the Eye
3.7
Patient Review
12/21/2013
Combigan for Increased Pressure in the Eye
3.7
Patient Review
2/6/2014
Combigan for Increased Pressure in the Eye
3.3
Patient Review
5/3/2014
Combigan for Wide-Angle Glaucoma
3.3
Patient Review
6/11/2014
Combigan for Increased Pressure in the Eye
3.3
Patient Review
9/15/2021
Combigan for Increased Pressure in the Eye
3
Patient Review
2/19/2018
Combigan for Wide-Angle Glaucoma
2.7
Patient Review
2/9/2018
Combigan for Wide-Angle Glaucoma
2.3
Patient Review
6/11/2014
Combigan for Increased Pressure in the Eye
2.3
Patient Review
10/25/2022
Combigan for Increased Pressure in the Eye
1
Patient Review
2/14/2014
Combigan for Wide-Angle Glaucoma
Patient Q&A Section about combigan
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
How long can I use Combigan?
"eye drops expire four weeks after opening"
Answered by AI
Is Combigan a good eye drop?
"Researchers examined the effect of Combigan and brimonidine 0.2% plus a beta-blocker on increased eye pressure in children aged 2-16. They found that Combigan is safe and effective for this purpose."
Answered by AI
What is the drug Combigan used to treat?
"This combination medication lowered high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). By lowering high pressure inside the eye, it helps to prevent blindness. This product contains brimonidine and timolol."
Answered by AI
What is the generic for Combigan?
"- The U.S. Food and Drug Administration today approved brimonidine tartrate/timolol maleate ophthalmic solution 0.2%/0.5% (Alphagan P/Travatan Z), a generic version of AbbVie Inc.'s Combigan, for the reduction of intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
The U.S. Food and Drug Administration today approved a generic version of AbbVie Inc.'s Combigan, for the reduction of intraocular pressure in patients with ocular hypertension or open-angle glaucoma."
Answered by AI